University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Sir Peter MacCallum Department of Oncology
  • Sir Peter MacCallum Department of Oncology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Sir Peter MacCallum Department of Oncology
  • Sir Peter MacCallum Department of Oncology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Benzenesulphonamide inhibitors of the cytolytic protein perforin

    Thumbnail
    Download
    published version (1018.Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    6
    5
    Author
    Spicer, JA; Miller, CK; O'Connor, PD; Jose, J; Huttunen, KM; Jaiswal, JK; Denny, WA; Akhlaghi, H; Browne, KA; Trapani, JA
    Date
    2017-02-15
    Source Title
    Bioorganic and Medicinal Chemistry Letters
    Publisher
    PERGAMON-ELSEVIER SCIENCE LTD
    University of Melbourne Author/s
    Trapani, Joseph
    Affiliation
    Sir Peter MacCallum Department of Oncology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Spicer, J. A., Miller, C. K., O'Connor, P. D., Jose, J., Huttunen, K. M., Jaiswal, J. K., Denny, W. A., Akhlaghi, H., Browne, K. A. & Trapani, J. A. (2017). Benzenesulphonamide inhibitors of the cytolytic protein perforin. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 27 (4), pp.1050-1054. https://doi.org/10.1016/j.bmcl.2016.12.057.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/257547
    DOI
    10.1016/j.bmcl.2016.12.057
    Abstract
    The pore-forming protein perforin is a key component of mammalian cell-mediated immunity and essential to the pathway that allows elimination of virus-infected and transformed cells. Perforin activity has also been implicated in certain auto-immune conditions and therapy-induced conditions such as allograft rejection and graft versus host disease. An inhibitor of perforin activity could be used as a highly specific immunosuppressive treatment for these conditions, with reduced side-effects compared to currently accepted therapies. Previously identified first-in-class inhibitors based on a 2-thioxoimidazolidin-4-one core show suboptimal physicochemical properties and toxicity toward the natural killer (NK) cells that secrete perforin in vivo. The current benzenesulphonamide-based series delivers a non-toxic bioisosteric replacement possessing improved solubility.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45689]
    • Sir Peter MacCallum Department of Oncology - Research Publications [728]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors